Bank of New York Mellon
ENZN

Bank of New York Mellon’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

Bank of New York Mellon’s Portfolio ENZN Stock Details ENZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-102,516
Closed -$49K – 4392
2016
Q1 		$49K Sell
102,516
-8,993
-8% -$4.39K ﹤0.01% 4089
2015
Q4 		$75K Buy
111,509
+5,845
+6% +$4.63K ﹤0.01% 4114
2015
Q3 		$102K Buy
105,664
+3,147
+3% +$3.87K ﹤0.01% 4104
2015
Q2 		$123K Buy
102,517
+7,048
+7% +$8.98K ﹤0.01% 4005
2015
Q1 		$101K Sell
95,469
-343
-0.4% -$355 ﹤0.01% 4043
2014
Q4 		$104K Buy
95,812
+344
+0.4% +$361 ﹤0.01% 4037
2014
Q3 		$104K Sell
95,468
-1
-0% -$1 ﹤0.01% 4046
2014
Q2 		$100K Sell
95,469
-164,267
-63% -$156K ﹤0.01% 3994
2014
Q1 		$268K Sell
259,736
-11,418
-4% -$11.8K ﹤0.01% 3767
2013
Q4 		$315K Sell
271,154
-77,924
-22% -$120K ﹤0.01% 3730
2013
Q3 		$586K Buy
349,078
+88,909
+34% +$165K ﹤0.01% 3462
2013
Q2 		$520K Buy
+260,169
New +$762K ﹤0.01% 3487

Other funds holding ENZN

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return
MCM
Monarch Capital Management Fort Wayne, Indiana $436M AUM 26.61% 1-Year Est. Return
CFA
CT Financial Advisors Chadds Ford, Pennsylvania $162M AUM 9.58% 1-Year Est. Return

Bank of New York Mellon's ENZN Position: Q2 2016 in Review

Bank of New York Mellon sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q2 2016, closing a stake of 102,516 shares — an estimated $49K sold.

Bank of New York Mellon first reported a position in ENZN in Q2 2013 and held it in 12 quarters. The position peaked at $586K in Q3 2013. 10 funds tracked by Wall St. Rank hold ENZN as of Q2 2016.

  • Bank of New York Mellon reported no remaining ENZON PHARMACEUTICALS INC position as of Q2 2016 after selling out during the quarter.
  • Bank of New York Mellon sold 102,516 ENZON PHARMACEUTICALS INC shares in Q2 2016, an estimated $49K.
  • Bank of New York Mellon first reported a position in ENZON PHARMACEUTICALS INC in Q2 2013 and held it in 12 quarters.
  • Bank of New York Mellon's ENZON PHARMACEUTICALS INC position peaked at $586K in Q3 2013.
  • 10 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q2 2016.

Based on Bank of New York Mellon's 13F filing for Q2 2016, filed 1 Aug 2016.